[{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Announces Dosing of First Participant With Metabolic Syndrome in Phase 1B Clinical Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Inversago Pharma"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Inversago Pharma"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Has Pre-IND Meeting with FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Arch Biopartners"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Cilastatin is an enzymatic dipeptidase-1 (DPEP-1) inhibitor, small molecule drug. It is being evaluated for the treatment of toxin related acute kidney injury.
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.
INV-202, first-in-class, peripheral CB1 inhibitor, demonstrated efficacy in addressing multiple pathways involved in renal injury also have shown clinical improvements in lipids, weight loss and glucose.